Enhanced AhR activity is associated with disease in autoimmune patients and preclinical models of disease, and AhR agonists have been shown to inhibit inflammation in models of inflammatory bowel disease, systemic lupus erythematosus, and rheumatoid arthritis (61–63). This evidence concerns the gene AHR and inflammatory bowel disease.